Cytonus Therapeutics Selected to Present at BIO CEO & Investor Conference in New York City

February 2, 2020


Cytonus Therapeutics Inc. today announces that it has been selected to present at next week’s BIO CEO & Investor Conference. Cytonus’ Founder and CEO Remo Moomiaie-Qajar, MD will present on Monday, February 10th at 10:45 am in the Ziegfeld Room at the New York Marriott Marquis. Cytonus is a leading cell-based platform technology company that has developed a vast platform of proprietary Cargocyte™ Adoptive Cellular Therapy (ACT) technologies which have numerous medical applications including immunotherapeutic products to treat cancers and inflammatory diseases and to improve patient outcomes. Its innovative platform of products has the potential to improve the health and lives of millions of people across the globe.

BIO CEO & Investor Conference, held February 10-11, is one of the Biotech industry’s prime occasions for life science entrepreneurs and investors to come together to discuss pipeline innovative technologies that will drive the future of healthcare. Now in its 22nd year, the BIO CEO & Investor Conference is one of the largest investor conferences focused on established and emerging publicly-traded and select private biotech companies.

Each year, the BIO CEO & Investor Conference provides a neutral forum where industry analysts, institutional investors, and senior biotechnology executives have the opportunity to shape the future investment landscape of the biotechnology industry. The conference features issue-oriented plenary sessions, educational sessions focused on key therapeutic areas in biopharma and business issues, and featured company presentations.

About Cytonus Therapeutics Inc.

Cytonus Therapeutics Inc. is a San Diego based biotech company that has developed a vast platform of proprietary immunotherapeutic products to treat a wide range of medical conditions including cancers, infectious diseases, inflammatory diseases and cognitive disorders, and to improve patient outcomes. Its proprietary Cargocyte™ technologies are next-generation biomolecular delivery devices which have numerous medical applications across unmet therapeutic areas. Cargocytes™ are engineered to safely transport a multiplicity of therapeutic payloads into difficult-to-reach targeted tissues, and can be programmed to deliver selective, potent, and controllable “off-the-shelf” therapies. Cytonus’ vast platform of therapeutics and vaccines has the potential to improve the health and lives of people with life-threatening conditions. For more information, we invite you to visit the Cytonus website at Please follow us on Cytonus on LinkedIn and on Twitter at: @CytonusTx.

Statements in this news release other than strictly historical facts, such as statements about Cytonus’ plans and strategies, new and existing products and technologies, anticipated clinical and regulatory pathways, and markets for its products, are forward-looking statements. The words “believe,” “expect,” “aim,” “anticipate,” “estimate,” “project,” and similar expressions identify forward-looking statements that speak only as of the date hereof. Such statements involve risks and uncertainties that could cause actual results to differ materially from anticipated results due to many factors, including regulatory and development risks. The company undertakes no obligation to publicly update or revise any forward-looking statement. This news release is neither an offer to sell, nor the solicitation of any offer to purchase, any security.

Join Cytonus on LinkedIn and follow its Twitter account at: @CytonusTx